- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SILEXION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13:42 | Silexion Therapeutics Corp: Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer | 77 | GlobeNewswire (Europe) | Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, integrated systemic treatment delivery approach targeting... ► Artikel lesen | |
| 13:42 | Silexion receives Israeli approval for pancreatic cancer trial | 1 | Investing.com | ||
| Mo | Silexion Therapeutics: Aktionäre lehnen Kapitalerhöhung und Ausweitung des Aktienplans ab | 2 | Investing.com Deutsch | ||
| Mo | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 17.03. | Silexion Therapeutics reports Q4 results | 1 | Seeking Alpha | ||
| 17.03. | Silexion Therapeutics Corp: Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | 264 | GlobeNewswire (Europe) | Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, including first evidence of activity in gastric cancer... ► Artikel lesen | |
| 17.03. | Silexion Therapeutics Corp - 10-K, Annual Report | 4 | SEC Filings | ||
| 19.02. | Silexion Therapeutics Corp - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 03.02. | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 21.01. | Silexion Therapeutics Corp: Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit | 2 | GlobeNewswire (USA) | ||
| 06.01. | Silexion Therapeutics Corp: Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025's Significant Achievements and Outlining Upcoming Milestones for 2026 | 309 | GlobeNewswire (Europe) | SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal, and Lung Cancer Models Company's Platform Seeks to Address an Estimated... ► Artikel lesen | |
| 06.01. | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 16.12.25 | Silexion Therapeutics Corp: Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer | 1 | GlobeNewswire (USA) | ||
| 16.12.25 | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 02.12.25 | Silexion Therapeutics Corp: Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer | 1 | GlobeNewswire (USA) | ||
| 02.12.25 | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 25.11.25 | Silexion Therapeutics Corp: Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer | 386 | GlobeNewswire (Europe) | Successful completion of two-species toxicology studies confirms no systemic organ toxicity, advancing the Company towards its planned regulatory submissions to Israel and Germany Company remains... ► Artikel lesen | |
| 25.11.25 | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 12.11.25 | Silexion Therapeutics GAAP EPS of -$2.88 | 2 | Seeking Alpha | ||
| 12.11.25 | Silexion Therapeutics Corp Announces Drop In Q3 Bottom Line | 3 | RTTNews |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 75,10 | -2,59 % | DEUTSCHE BANK RESEARCH stuft Biontech auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Biontech mit einem Kursziel von 140 US-Dollar auf "Buy" belassen. Der Antikörperspezialist habe einen etwas verwirrenden... ► Artikel lesen | |
| AMGEN | 303,00 | +0,61 % | Defensive Biotech-Wetten? Warum Amgen und AbbVie strukturell wachsen - kleiner Player Mesoblast im Fokus | ||
| NOVAVAX | 8,185 | -2,06 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| BIOGEN | 157,90 | -0,35 % | Biogen Inc.: Results from Real-World, Long-Term Treatment Persistence with LEQEMBI (lecanemab-irmb) in the United States Presented at AD/PD 2026 | TOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,805 | -0,61 % | Why Viking Therapeutics Stock Could Take Off Later This Year | ||
| MAINZ BIOMED | 0,462 | -2,39 % | Quantum Cyber Aligns Strategy With Trump Administration's National Cyber Security Framework, Targets Acquisitions in Quantum and Cyber Defense Sectors | BERKELEY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: QUCY) doing business as Quantum Cyber (the "Company" or "Quantum Cyber"), today announced a strategic update in response... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,110 | -0,63 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM | CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| TEMPUS AI | 42,200 | +3,43 % | Tempus AI Quartalszahlen: 90 % Umsatzplus bestätigen KI-Trend in der Medizin | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat seine Ergebnisse für das vierte Quartal 2025 veröffentlicht und ein rasantes Umsatzwachstum verzeichnet. Tempus AI -... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,280 | -4,30 % | BioCryst (BCRX) Rallies 7.10% on Acquisition Buzz | ||
| BIOMARIN PHARMACEUTICAL | 47,150 | +0,81 % | BioMarin Pharmaceutical (BMRN) Reports Positive Results From Ongoing Trials of VOXZOGO | ||
| SAREPTA THERAPEUTICS | 15,205 | +5,04 % | Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies | ||
| EXELIXIS | 35,560 | -0,28 % | Exelixis-Aktie: Blockbuster-Kandidat Zanzalintinib vor Zulassung | Auf der Suche nach wachstumsstarken Biotech-Unternehmen mit angemessener Bewertung rückt Exelixis ins Blickfeld. Der Onkologiespezialist ist profitabel, verfügt über mehrere in den USA vermarktete Therapien... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,167 | +1,87 % | Canaccord reiterates Pacific Biosciences stock rating on new chemistry | ||
| CARDIOL THERAPEUTICS | 0,890 | +10,42 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference | Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing... ► Artikel lesen | |
| VAXART | 0,630 | +50,00 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen |
Das Unternehmen SILEXION THERAPEUTICS CORP kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -6,87 % bei einem Aktienkurs von 1,220 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SILEXION THERAPEUTICS CORP finden Sie auf Wallstreet Online.